Teclistamab, Other BCMA-Targeted Agents Represent New Options in Relapsed/Refractory Myeloma

Andrew Kin, MD, expands on the ways BCMA-targeted therapies that are currently available and under development have shifted the treatment landscape for relapsed/refractory multiple myeloma, the implications of the approval of teclistamab, and the limitations that still exist for using BCMA-targeted agents.

Related Keywords

Michigan ,United States , ,Barbara Ann Karmanos Cancer Institute ,Andrew Kin ,Science Summit ,D ,Teclistamab ,Bcma Targeted Therapies For Patients With Relapsed Refractory Multiple Myeloma ,Multiple Myeloma Treatment Landscape ,Relapsed Refractory Multiple Myeloma ,Development And Emergence Of Bcma Targeted Agents In Multiple Myeloma ,Belantamab Mafodotin ,Patients With Penta Refractory Multiple Myeloma ,